AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ANATARA LIFESCIENCES LTD

0.007

0.000

Volume:174.07K

Turnover:1.22K

Market Cap:1.49M

PE:-0.67

High:0.007

Open:0.007

Low:0.007

Close:0.007

Loading ...

Overview Company News Filings

ASX ALERT-Company Update-ANR.AX

Anatara Lifesciences Gets Hong Kong Patent for Gastrointestinal Re-Programming Product; Shares Fall 8%

MT Newswires Live

BRIEF-Anatara Lifesciences Says Hong Kong Patent Granted For GARP Product

Anatara Lifesciences Ltd - Hong Kong Patent Granted for Garp Product

THOMSON REUTERS

Anatara Lifesciences Says Phase Two Trial Unlikely to Achieve Primary Endpoint; Shares Fall 74% to All-Time Low

MT Newswires Live

BRIEF-Anatara Lifesciences Seeks Trading Halt Pending Announcement Regarding Update On Phase II Garp-Ibs Trial

Anatara Lifesciences Ltd - Seeks Trading Halt Pending Announcement Regarding Update on Phase Ii Garp-Ibs Trial

THOMSON REUTERS

Anatara Lifesciences Receives Australian Patent for Gastrointestinal Product; Shares Fall 8%

MT Newswires Live

BRIEF-Anatara Lifesciences Says Australian Patent Granted For GARP Product

Anatara Lifesciences Ltd - Australian Patent Granted for Garp Product

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ANR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ANR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANR.AU\",,,,,undefined,":{"symbol":"ANR.AU","market":"AU","secType":"STK","nameCN":"ANATARA LIFESCIENCES LTD","latestPrice":0.007,"timestamp":1754028720000,"preClose":0.007,"halted":0,"volume":174068,"delay":0,"nameEN":"ANATARA LIFESCIENCES LTD","floatShares":125359802,"shares":213383727,"eps":-0.010438,"marketStatus":"Market Closed","change":0,"latestTime":"08-01 16:12:00 AEST","open":0.007,"high":0.007,"low":0.007,"amount":1218,"amplitude":0,"askPrice":0.008,"askSize":513449,"bidPrice":0.006,"bidSize":2895493,"shortable":3,"etf":0,"ttmEps":-0.010438,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1754265600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.007,"openAndCloseTimeList":[[1754006400000,1754028000000]],"volumeRatio":0.046853675099609526,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANR.AU\",,,,,undefined,":{"symbol":"ANR.AU","floatShares":125359802,"roa":"-76.07%","roe":"-147.32%","lyrEps":-0.009673,"volumeRatio":0.046853675099609526,"shares":213383727,"dividePrice":0,"high":0.007,"amplitude":0,"preClose":0.007,"low":0.007,"week52Low":0.004,"pbRate":"1.10","psRate":"5.96","week52High":0.073,"institutionHeld":0,"latestPrice":0.007,"committee":0.698763,"eps":-0.010438,"divideRate":0,"volume":174068,"delay":0,"ttmEps":-0.010438,"open":0.007,"prevYearClose":0.047,"prevWeekClose":0.008,"prevMonthClose":0.007,"prevQuarterClose":0.005,"fiveDayClose":0.008,"twentyDayClose":0.006,"sixtyDayClose":0.006},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ANR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550579718","title":"ASX ALERT-Company Update-ANR.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550579718","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550579718?lang=en_us&edition=fundamental","pubTime":"2025-07-09 07:20","pubTimestamp":1752016801,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250708:nASX5H0xn7","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nASXc1Dckg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ANR.AU","BK7508"],"gpt_icon":0},{"id":"2536526117","title":"Anatara Lifesciences Gets Hong Kong Patent for Gastrointestinal Re-Programming Product; Shares Fall 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536526117","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536526117?lang=en_us&edition=fundamental","pubTime":"2025-05-19 11:15","pubTimestamp":1747624527,"startTime":"0","endTime":"0","summary":"Anatara Lifesciences  obtained a standard patent for its gastrointestinal re-programming product, known as GaRP, in Hong Kong, according to a Monday filing with the Australian bourse.The patent is valid for 20 years from Oct. 9, 2020, and follows a similar grant from the European Union in September 2024, and in Australia on Jan. 28 of this year.Anatara Lifesciences recently concluded its trial for GaRP as treatment for debilitating symptoms of digestive disorders, including irritable bowel syndrome , per the filing.Anatara Lifesciences' shares fell 8% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","ANR.AU","BK7508","XAO.AU","XKO.AU","BK7067"],"gpt_icon":0},{"id":"2536154904","title":"BRIEF-Anatara Lifesciences Says Hong Kong Patent Granted For GARP Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2536154904","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536154904?lang=en_us&edition=fundamental","pubTime":"2025-05-19 09:34","pubTimestamp":1747618441,"startTime":"0","endTime":"0","summary":"BRIEF-Anatara Lifesciences Says Hong Kong Patent Granted For GARP ProductMay 19 (Reuters) - Anatara Lifesciences Ltd ANR.AX:HONG KONG PATENT GRANTED FOR GARP PRODUCTFurther company coverage: ANR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nFWN3RO1R7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANR.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2536517451","title":"Anatara Lifesciences Ltd - Hong Kong Patent Granted for Garp Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2536517451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536517451?lang=en_us&edition=fundamental","pubTime":"2025-05-19 07:58","pubTimestamp":1747612732,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250518:nFWN3RO1R7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","ANR.AU"],"gpt_icon":0},{"id":"2518697342","title":"Anatara Lifesciences Says Phase Two Trial Unlikely to Achieve Primary Endpoint; Shares Fall 74% to All-Time Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2518697342","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518697342?lang=en_us&edition=fundamental","pubTime":"2025-03-10 13:11","pubTimestamp":1741583512,"startTime":"0","endTime":"0","summary":"Anatara Lifesciences  said it is unlikely to achieve a statistically significant improvement in irritable bowel syndrome severity scoring system when compared to placebo in the second stage of the phase two Gastrointestinal ReProgramming-IBS trial based on preliminary analysis, according to a Monday Australian bourse filing.It said the second stage of the trial moved into the database lock process after all participants completed the mandatory two-week follow-up period.The final fully assessable number of participants has been reduced to 62 from 71 after the assessment of participant numbers for both compliance and entry criteria.The second stage included a planned extension of the phase two trial, following the successful completion of stage 1 which reported on 20 patients with a greater than 50% reduction in IBS symptoms and with a safety profile confirmed.It added that its planned anti-obesity in-vivo pre-clinical experiments are now underway following agreements with the University","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANR.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2517972605","title":"BRIEF-Anatara Lifesciences Seeks Trading Halt Pending Announcement Regarding Update On Phase II Garp-Ibs Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2517972605","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517972605?lang=en_us&edition=fundamental","pubTime":"2025-03-06 09:37","pubTimestamp":1741225061,"startTime":"0","endTime":"0","summary":"BRIEF-Anatara Lifesciences Seeks Trading Halt Pending Announcement Regarding Update On Phase II Garp-Ibs TrialMarch 6  - Anatara Lifesciences Ltd ANR.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT REGARDING  UPDATE ON PHASE II GARP-IBS TRIALFurther company coverage: ANR.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO16D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ANR.AU","BK7508"],"gpt_icon":0},{"id":"2517227539","title":"Anatara Lifesciences Ltd -  Seeks Trading Halt Pending Announcement Regarding  Update on Phase Ii Garp-Ibs Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2517227539","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517227539?lang=en_us&edition=fundamental","pubTime":"2025-03-06 06:03","pubTimestamp":1741212213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO16D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ANR.AU"],"gpt_icon":0},{"id":"2507574784","title":"Anatara Lifesciences Receives Australian Patent for Gastrointestinal Product; Shares Fall 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507574784","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507574784?lang=en_us&edition=fundamental","pubTime":"2025-01-29 10:43","pubTimestamp":1738118581,"startTime":"0","endTime":"0","summary":"Anatara Lifesciences  received a patent for its Gastrointestinal ReProgramming   product, under the invention title \"Gastrointestinal Health Composition,\" according to a Tuesday filing with the Australian bourse.The intellectual property protection, granted by the Australian Patent Office, has a 20-year term from Oct. 9, 2020, to Oct. 9, 2040, the filing said.The GaRP product is a complementary medicine designed to tackle the root causes of chronic gastrointestinal conditions like irritable bowel syndrome and inflammatory bowel disease, per the filing.Its shares fell 8% in afternoon trade Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANR.AU","XAO.AU","XKO.AU","BK7067","XJO.AU","BK7508"],"gpt_icon":0},{"id":"2506530875","title":"BRIEF-Anatara Lifesciences Says Australian Patent Granted For GARP Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2506530875","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506530875?lang=en_us&edition=fundamental","pubTime":"2025-01-28 09:03","pubTimestamp":1738026192,"startTime":"0","endTime":"0","summary":"BRIEF-Anatara Lifesciences Says Australian Patent Granted For GARP ProductJan 28 (Reuters) - Anatara Lifesciences Ltd ANR.AX:AUSTRALIAN PATENT GRANTED FOR GARP PRODUCTFurther company coverage: ANR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3ON170:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANR.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2506531430","title":"Anatara Lifesciences Ltd - Australian Patent Granted for Garp Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2506531430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506531430?lang=en_us&edition=fundamental","pubTime":"2025-01-28 07:45","pubTimestamp":1738021548,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nFWN3ON170:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ANR.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANR.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANR.AU\",market:\"AU\",,,undefined,":[]}}